AVPR1B
Vasopressin V1b receptor
As of the edition of 20 October 2026, AVPR1B (vasopressin V1b receptor, UniProt P47901) has 8 drugs tested at it and 15 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P47901
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Hormones; Digestive system; Heart and blood vessels; Mental health; Infections; Nervous system
- Registered trials of its drugs
- 205
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Desmopressin | Marketed | Phase 4 | none listed |
| Vasopressin | Marketed | Phase 4 | none listed |
| Terlipressin | Marketed | Phase 4 | Ends 2029 |
| Nelivaptan | Went quiet | Phase 2 | none listed |
| ABT-436 | Stopped | Phase 2 | none listed |
| Argipressin tannate | Marketed | Phase 4 | none listed |
| Lypressin | Marketed | No phase stated | none listed |
| Vasopressin tannate | Marketed | No phase stated | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Undetermined | 11 |
| Total on the list | 15 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| AbbVie | Route A |
| Byk-Mallinckrodt CIL | Route B |
The other 12 companies at AVPR1B
In the product15 companies in all; 12 are not named here, and no score is.
See the 15 companies at AVPR1B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.